Literature DB >> 32645193

FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC.

Kevin M Wright.   

Abstract

The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32645193

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


  4 in total

Review 1.  Coming of Age of Immunotherapy of Urothelial Cancer.

Authors:  Enrique Grande; Javier Molina-Cerrillo; Andrea Necchi
Journal:  Target Oncol       Date:  2021-03-12       Impact factor: 4.493

Review 2.  Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective.

Authors:  Jeremy Yuen-Chun Teoh; Ashish M Kamat; Peter C Black; Petros Grivas; Shahrokh F Shariat; Marek Babjuk
Journal:  Nat Rev Urol       Date:  2022-03-31       Impact factor: 16.430

Review 3.  Biomarker-Oriented Therapy in Bladder and Renal Cancer.

Authors:  Mathijs P Scholtes; Arnout R Alberts; Iris G Iflé; Paul C M S Verhagen; Astrid A M van der Veldt; Tahlita C M Zuiverloon
Journal:  Int J Mol Sci       Date:  2021-03-11       Impact factor: 5.923

4.  Bladder rupture after pembrolizumab immunotherapy for bladder cancer: a case report.

Authors:  Ahmed Badheeb; Omar Alkhanbashi; Slah Rakrouki; Tahir Mahmood; Mashhoor Alqannas; Mohamed Badheeb; Faisal Ahmed
Journal:  Pan Afr Med J       Date:  2022-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.